HRPC(SH:600829)2019-04-12 16:00Financial Performance - Operating revenue for the first quarter reached CNY 1,965,282,033.07, representing a growth of 15.20% year-on-year[7] - Net profit attributable to shareholders was CNY 73,518,815.85, an increase of 5.78% compared to the same period last year[7] - Basic earnings per share rose by 5.75% to CNY 0.1268 compared to the previous year[7] - The net profit after deducting non-recurring gains and losses was CNY 72,416,060.27, reflecting a year-on-year increase of 4.44%[7] - Net profit for Q1 2019 was ¥73,508,657.72, representing a 5.4% increase from ¥69,501,179.58 in Q1 2018[27] - The company reported a total comprehensive income of CNY 73,508,657.72 for Q1 2019, compared to CNY 69,501,179.58 in Q1 2018[30] Cash Flow - The net cash flow from operating activities was negative at CNY -299,241,503.27, a decline of 262.03% year-on-year[7] - The cash flow from operating activities showed a net outflow of CNY 299,241,503.27, compared to a net inflow of CNY 184,685,250.44 in Q1 2018[33] - The cash flow from operating activities showed a significant outflow, with total cash outflow amounting to 166,439,179.36 RMB in Q1 2019[35] - The company experienced a net decrease in cash and cash equivalents of -4,305,406.38 RMB in Q1 2019, contrasting with an increase of 11,850,526.25 RMB in Q1 2018[36] Assets and Liabilities - Total assets increased by 3.20% to CNY 4,553,420,622.96 compared to the end of the previous year[7] - Accounts receivable increased to ¥2,967,529,357.50, up 20.00% from ¥2,471,035,722.38 year-over-year[18] - The company's total liabilities amounted to ¥2,899,973,089.47, compared to ¥2,832,415,012.35 previously[20] - Total assets reached ¥4,553,420,622.96, an increase from ¥4,412,353,888.12 at the end of the previous year[19] - Short-term borrowings rose to ¥324,000,000.00, up from ¥224,000,000.00, reflecting increased financing needs[19] Shareholder Information - The total number of shareholders reached 21,137 by the end of the reporting period[11] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holds 74.82% of the shares[11] Government Support - The company received government subsidies amounting to CNY 1,449,888.87 during the reporting period[9] Financial Expenses - Financial expenses decreased by 75.50% to ¥1,941,983.60 from ¥7,926,888.14 due to reduced discount interest[18] - The financial expenses for Q1 2019 were reduced to ¥1,941,983.60 from ¥7,926,888.14, a decrease of 75.5%[26] Mixed Ownership Reform - The company is undergoing mixed ownership reform, with a planned capital increase of ¥1.5 billion by CITIC Capital[14] - The company has completed the evaluation of all shareholder values as of September 30, 2018, and is preparing a mixed reform plan for approval[14]